Search results for " Leukemia"

showing 10 items of 666 documents

Distinct 5' SCL enhancers direct transcription to developing brain, spinal cord, and endothelium: neural expression is mediated by GATA factor bindin…

1999

The SCL gene encodes a basic helix-loop-helix transcription factor with a pivotal role in the development of endothelium and of all hematopoietic lineages. SCL is also expressed in the central nervous system, although its expression pattern has not been examined in detail and its function in neural development is unknown. In this article we present the first analysis of SCL transcriptional regulation in vivo. We have identified three spatially distinct regulatory modules, each of which was both necessary and sufficient to direct reporter gene expression in vivo to three different regions within the normal SCL expression domain, namely, developing endothelium, midbrain, and hindbrain/spinal …

animal structuresEmbryo NonmammalianTranscription GeneticHindbrainMice TransgenicChick EmbryoBiologybehavioral disciplines and activities03 medical and health sciencesMice0302 clinical medicineTranscription (biology)Genes Reporterhemic and lymphatic diseasesProto-Oncogene ProteinsBasic Helix-Loop-Helix Transcription FactorsAnimalsTissue DistributionEndotheliumEnhancerMolecular BiologyTranscription factorGeneIn Situ HybridizationT-Cell Acute Lymphocytic Leukemia Protein 1Zebrafish030304 developmental biologyRegulation of gene expressionGenetics0303 health sciencesReporter geneModels GeneticfungiBrainCell BiologyZebrafish ProteinsEmbryo MammalianCell biologyDNA-Binding ProteinsLac OperonSpinal CordNeural development030217 neurology & neurosurgeryDevelopmental BiologyTranscription FactorsDevelopmental biology
researchProduct

NFATc1 Is Transcriptionally Activated in Chronic Lymphocytic Leukemia (CLL) By Promotor DNA-Hypomethylation Which Correlates with in-Vitro Vulnerabil…

2014

Abstract Chronic lymphocytic leukemia (CLL), the most frequent adult leukemia in Western countries, is characterized by progressive accumulation of mature, monoclonal B lymphocytes in blood, bone marrow, and lymphoid tissues. In the pathogenesis and treatment of CLL, B cell receptor (BCR) signaling plays a crucial role, and aberrations in downstream pathways that become activated in CLL need to be better defined. One downstream target of BCR signaling is NFATc1, a transcription factor with a high oncogenic and transforming potential. Employing a genome-wide comparative DNA methylation analysis the NFATc1 5’ region was identified to be DNA hypomethylated in CLL patient samples. The pilot ser…

biologyChronic lymphocytic leukemiaImmunologyB-cell receptorbreakpoint cluster regionPromoterCell BiologyHematologymedicine.diseaseBiochemistryCD19Leukemiahemic and lymphatic diseasesDNA methylationmedicineCancer researchbiology.proteinDNA hypomethylationBlood
researchProduct

Drivers of topoisomerase II poisoning mimic and complement cytotoxicity in AML cells

2019

Recently approved cancer drugs remain out-of-reach to most patients due to prohibitive costs and only few produce clinically meaningful benefits. An untapped alternative is to enhance the efficacy and safety of existing cancer drugs. We hypothesized that the response to topoisomerase II poisons, a very successful group of cancer drugs, can be improved by considering treatment-associated transcript levels. To this end, we analyzed transcriptomes from Acute Myeloid Leukemia (AML) cell lines treated with the topoisomerase II poison etoposide. Using complementary criteria of co-regulation within networks and of essentiality for cell survival, we identified and functionally confirmed 11 druggabl…

biologyCombination therapybusiness.industryTopoisomeraseMyeloid leukemiatopoisomerase II poisonscombination therapyCell killingOncologygene expressioncancer essentialitybiology.proteinmedicineCancer researchDNA damageCytotoxic T cellCytotoxicitybusinessEtoposidePI3K/AKT/mTOR pathwayResearch Papermedicine.drugOncotarget
researchProduct

Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin wit…

2018

Abstract Background: Target inhibition of FLT3 by therapy with the recently FDA- and EMA-approved multi-targeted tyrosine kinase inhibitor (TKI) midostaurin can be monitored by plasma inhibitor activity (PIA) analysis by visualizing the level of target-dephosphorylation as previously described. When combining intensive chemotherapy with midostaurin, we have recently shown that the TKI achieves the lowest level of FLT3 phosphorylation (p-FLT3) at the end of the 1st induction cycle, indicating a deep target inhibition. However, sufficient inhibition could not be maintained during subsequent cycles by midostaurin in combination with chemotherapy, but it was reestablished during maintenance the…

business.industryImmunologyMyeloid leukemiaCell BiologyHematologyBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisCancer researchMedicinePhosphorylationFlt3 ligandIn patientMidostaurinbusiness030215 immunologyFlt3 itdBlood
researchProduct

Gene Expression Profile of Chronic Myeloid Leukemia Innately Resistant to Imatinib

2007

Background. Most chronic myeloid leukemia patients who receive imatinib as first line-terapy will obtain, after 12 months treatment, complete cytogenetic and molecular response . However several cases will not achieve molecular response, but their innate mechanism(s) of resistance remain poorly understood. We tried to explore the molecular events involved in innate resistance in CML. Study design. Five patients who were molecular “non responder” and seven “major” responder were investigated by using the expression profile of a set of 380 genes. Multiple testing procedure (MTP), Significance Analysis of Microarrays (SAM), Empirical Bayes Analysis of Microarrays (EBAM), False Discovery Rate (…

business.industryMyeloid leukemiaImatinibGeneral MedicineCell cycleMolecular ResponseImmunologySignificance analysis of microarraysCancer researchmedicineEpigeneticsDNA microarraybusinessGenemedicine.drugClinical Leukemia
researchProduct

Acute Myeloid Leukemia in Adults

2018

AML is a malignancy of hematopoietic immature precursors (myeloblasts) that accumulate in the BM at the expense of their normal counterparts.

business.industryMyeloid leukemiaMalignancymedicine.disease03 medical and health sciencesHaematopoiesis0302 clinical medicineText mininghemic and lymphatic diseases030220 oncology & carcinogenesisCancer researchmedicinebusinessneoplasms030215 immunology
researchProduct

Overcoming Imatinib resistance using CAI, a calcium-mediated signal transduction inhibitor: A new therapeutic strategy for chronic myelogenous leucem…

2008

carboxyamdotriazoleImatinib resistanceChronic Myelogenous Leukemia
researchProduct

Molecular profiling of chronic myelogenous leukemia cell lines: identification of new molecular markers for the characterization of leukemia phenotype

2009

chronic myelogenous leukemiaProteome profiling
researchProduct

Chronic myeloid leukemia as second malignancy; restrospective multicentric study

2009

chronic myeloid leukemia second malignancySettore MED/15 - Malattie Del Sangue
researchProduct

Chronic myeloid leukemia as second malignancy; a retrospective multicentrico study

2009

chronic myeloid leukemia secondary malignancySettore MED/15 - Malattie Del Sangue
researchProduct